Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bulk RNA-seq of HCT116 colorectal cancer 3D spheroids treated with 5-fluorouracil or olaparib

ABSTRACT: This study accompanies an adapted Cell Painting assay applied to 3D colorectal cancer spheroids (BioStudies S-BIAD2254). To relate image-based morphological profiles to transcriptional responses, bulk 3'-end RNA-seq was performed on HCT116 spheroids grown in ultra-low attachment 384-well plates and treated for 48 h with 5-fluorouracil (10 uM), olaparib (3 uM), or 0.1% DMSO vehicle. Gene-level differential expression and Hallmark pathway enrichment were used to characterise the drug-induced transcriptional programs underlying the observed morphological phenotypes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE343958 | GEO | 2026/08/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Bulk RNA-seq of HCT116 colorectal cancer 3D spheroids treated with 5-fluorouracil or olaparib

Project description:Bulk RNA-seq of HCT116 colorectal cancer 3D spheroids treated with 5-fluorouracil or olaparib

| PRJNA1514004 | ENA

Olaparib

Project description:Olaparib

| PRJEB6685 | ENA

Genome-wide analysis of enzalutamide- and/or olaparib-responsive gene expression in prostate cancer cells

Project description:Analysis of enzalutamide- and/or olaparib-responsive gene expression in prostate cancer cells. The hypothesis tested in the present study was that enzalutamide influences the expression of genes that are involved in important bioprocesses in prostate cance rcells, including DNA damage response genes and this effect may synergize with poly(ADP-ribose) polymerase inhibitor olaparib in cytotoxicity to prstate cancer cells. prostate cancer cells were pretreated with enzalutamide or vehicle control DMSO for 24 h, followed by treatment with enzalutamide, olaparib, enzalutamide+olaparib, or vehicle control DMSO for 48 h. Gene expression in enzalutamide+olaparib-treated cells was compared with taht in vehicle control- and single agent-treated cells.

2016-07-03 | E-GEOD-69249 | biostudies-arrayexpress

Activation of Wnt signaling promotes olaparib resistant ovarian cancer.

Project description:Sequencing of olaparib-resistant PEO1 derivatives (C4, C5, C10 and C18) and parental PEO1 (P1 and P2) cells was performed in order to determine mechanisms of acquired resistance in the resistant cell lines. PEO1 parental cell lines were authenticated prior to sequencing. PEO1 parental were confirmed to be BRCA2-mutated (5139C>G). Olaparib PEO1 resistant cells were generated through a step-wise escalation of olaparib (10nM to 8uM olaparib). In olaparib resistant lines an increase canonical Wnt signaling and loss of of non-canonical Wnt signaling was observed.

2018-07-28 | GSE117765 | GEO

Transcriptome profiling of Olaparib-resistant (OlapR) prostate cancer cell lines

Project description:Acquisition of resistance to the PARP inhibitor, Olaparib, constitutes a major challenge for the treatment of advanced prostate cancer. The purpose of this study was to identify molecular targets responsible for the development of acquired Olaparib resistance in advanced prostate cancer. Towards this goal, next-generation sequencing (NGS)-based gene expression profiling (RNA-Sequencing; RNA-Seq) was performed on castration-sensitive prostate cancer (CSPC)/Olaparib-sensitive LNCaP cells, castration-sensitive prostate cancer (CSPC)/Olaparib-resistant LN-OlapR cells, castration-resistant prostate cancer (CSPC)/Olaparib-sensitive C4-2B cells, and castration-resistant prostate cancer (CSPC)/Olaparib-resistant 2B-OlapR cells.

2023-12-06 | GSE249514 | GEO

Denunded HUVEC/HUASMC spheroids vs. HUASMC spheroids

Project description:Denunded HUVEC/HUASMC spheroids vs. HUASMC spheroids

| PRJNA657248 | ENA

Transcriptome analysis of Hela cells treated with the PARP inhibitor Olaparib.

Project description:In total, 17,118 and 16,786 transcripts were detected in olaparib- and DMSO-treated cells, respectively. Analysis of differentially expressed genes (DEGs) revealed 866 genes, including 503 upregulated and 363 downregulated genes in olaparib-treated cells). Volcano plots indicated the upregulation of inflammatory cytokine-related genes . Enrichment analyses using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database20,21 identified inflammation-related pathways as prominently upregulated in olaparib-treated cells, with five of the top 10 pathways involving inflammation-related genes. Dot plot analyses also confirmed the upregulation of inflammatory hallmarks, such as TNFA signaling via NFκB, inflammatory response, IL2-STAT5 signaling and interferon gamma response, in olaparib-treated cells. Furthermore, the GSEA determined significant enrichment of inflammatory cytokine-related KEGG pathways, including cytokine–cytokine receptor interaction, JAK-STAT signaling, and Rig I like receptor signaling pathways, as well as inflammatory hallmarks such as TNFA signaling via NFκB, interferon alfa response, and interferon gamma response in olaparib-treated cells.

2025-06-01 | GSE298546 | GEO

Gene epression profile of s-spheroids and t-spheroids differentiated from iPS cells

Project description:For definitive endoderm differentiation, iPS cells (day0) were treated with 100 ng ml-1 activin A and 3μM CHIR99021 for 1 day and 100 ng ml-1 activin A for the following two days. Definitive endoderm was subsequently treated with 3uM CHIR99021 and 500ng ml-1 FGF4 for mid/hindgut differentiation. Mid/hindgut floating spheroids (fl; t-Spheroids) were collected from culture medium from day6 to day 8. On day6, mid/hindgut cells were dissociated into single cells and seeded onto EZSPHERE plate to generate suspension spheroids(EZ; s-Spheroids). RNA of fl spheroids and EZ spheroids were extracted using QIAGEN RNeasy kit.

2022-11-15 | GSE182230 | GEO

The effect of Olaparib or MNA on bone marrow derived macrophage gene expression during induction

Project description:To investigate the effect of olaparib or MNA on macrophage, we treated bone marrow with olaparib or MNA during BMDM induction for 6 days.

2022-08-05 | GSE210378 | GEO

Genome-wide CRISPR knockout screen using GeCKO v2 to identify synthetic lethal interactions with the PARP inhibitor Olaparib

Project description:In this study, a population of knockout cells was generated using the GeCKO v2 sgRNA library. The population of knockout cells was treated with the PARP inhibitor olaparib for 14 days. Over this time, knockout cells that were sensitive to olaparib treatment would die and a population of knockout cells that was resistant to olaparib treatment remained. Cells from olaparib and DMSO conditions and the sgRNA cassette in the knockout cells was amplified and sequenced to identify synthetic lethal or suppressor interactions with olaparib treatment.

2020-08-01 | GSE145743 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data